Bill Loguidice | Authors


New Collaboration Forms for Immunotherapy Regimens in Hematologic Malignancies

April 27, 2015

MedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sàrl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.